Role of Sport Activity on Quality of Life in Charcot-Marie-Tooth 1A Patients
Abstract
:1. Introduction
2. Materials and Methods
2.1. Questionnaires
2.1.1. Sport and Motivational Effects of Physical Activity Performance
2.1.2. Self-Esteem, Depression, and Quality of Life
2.1.3. Pain
2.2. Statistical Analisys
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Depauw, K. Disability Sport: Historical Context; Routledge: New York, NY, USA, 2008; ISBN 9780203889732. [Google Scholar]
- Webborn, N.; Van De Vliet, P. Paralympic medicine. Lancet 2012, 380, 65–71. [Google Scholar] [CrossRef]
- Vita, G.L.; Stancanelli, C.; La Foresta, S.; Faraone, C.; Sframeli, M.; Ferrero, A.; Fattore, C.; Galbo, R.; Ferraro, M.; Ricci, G.; et al. Psychosocial impact of sport activity in neuromuscular disorders. Neurol. Sci. 2020, 41, 2561–2567. [Google Scholar] [CrossRef]
- Castelli, L.; De Giglio, L.; Haggiag, S.; Traini, A.; De Luca, F.; Ruggieri, S.; Prosperini, L. Premorbid functional reserve modulates the effect of rehabilitation in multiple sclerosis. Neurol. Sci. 2020, 5, 1251–1257. [Google Scholar] [CrossRef]
- Laudisio, A.; Giovannini, S.; Finamore, P.; Loreti, C.; Vannetti, F.; Coraci, D.; Incalzi, R.A.; Zuccal, G.; Macchi, C.; Padua, L.; et al. Muscle strength is related to mental and physical quality of life in the oldest old. Arch. Gerontol. Geriatr. 2020, 89, 104109. [Google Scholar] [CrossRef]
- Blauwet, C.; Willick, S.E. The paralympic movement: Using sports to promote health, disability rights, and social integration for athletes with disabilities. PM R J. Inj. Funct. Rehabil. 2012, 4, 851–856. [Google Scholar] [CrossRef]
- Giovannini, S.; Macchi, C.; Liperoti, R.; Laudisio, A.; Coraci, D.; Loreti, C.; Vannetti, F.; Onder, G.; Padua, L.; Bonaccorsi, G.; et al. Association of Body Fat With Health-Related Quality of Life and Depression in Nonagenarians: The Mugello Study. J. Am. Med. Dir. Assoc. 2019, 20, 564–568. [Google Scholar] [CrossRef]
- Pareyson, D.; Scaioli, V.; Laurà, M. Clinical and electrophysiological aspects of charcot-marie-tooth disease. Neuromolecular Med. 2006, 8, 3–22. [Google Scholar] [CrossRef]
- Boerkoel, C.F.; Takashima, H.; Garcia, C.A.; Olney, R.K.; Johnson, J.; Berry, K.; Russo, P.; Kennedy, S.; Teebi, A.S.; Scavina, M.; et al. Charcot-Marie-Tooth disease and related neuropathies: Mutation distribution and genotype-phenotype correlation. Ann. Neurol. 2002, 51, 190–201. [Google Scholar] [CrossRef]
- Verhamme, C.; De Haan, R.J.; Vermeulen, M.; Baas, F.; De Visser, M.; Van Schaik, I.N. Oral high dose ascorbic acid treatment for one year in young CMT1A patients: A randomised, double-blind, placebo-controlled phase II trial. BMC Med. 2009, 7, 70. [Google Scholar] [CrossRef]
- Burns, J.; Ouvrier, R.A.; Yiu, E.M.; Joseph, P.D.; Kornberg, A.J.; Fahey, M.C.; Ryan, M.M. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: A randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 2009, 8, 537–544. [Google Scholar] [CrossRef]
- Toth, C. Poor tolerability of high dose ascorbic acid in a population of genetically confirmed adult Charcot-Marie-Tooth 1A patients. Acta Neurol. Scand. 2009, 120, 134–138. [Google Scholar]
- Pareyson, D.; Schenone, A.; Fabrizi, G.M.; Santoro, L.; Padua, L.; Quattrone, A.; Vita, G.; Gemignani, F.; Visioli, F.; Solari, A.; et al. A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): The study protocol [EudraCT no.: 2006-000032-27]. Pharmacol. Res. 2006, 54, 436–441. [Google Scholar] [CrossRef]
- Attarian, S.; Vallat, J.M.; Magy, L.; Funalot, B.; Gonnaud, P.M.; Lacour, A.; Péréon, Y.; Dubourg, O.; Pouget, J.; Micallef, J.; et al. An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J. Rare Dis. 2014, 9, 199, Erratum in Orphanet J. Rare Dis. 2016, 11, 92. [Google Scholar] [CrossRef]
- Kiepura, A.J.; Kochański, A. Charcot-Marie-Tooth type 1A drug therapies: Role of adenylyl cyclase activity and G-protein coupled receptors in disease pathomechanism. Acta Neurobiol. Exp. 2018, 78, 198–209. [Google Scholar]
- Anziska, Y.; Inan, S. Exercise in neuromuscular disease. Semin. Neurol. 2014, 34, 542–556. [Google Scholar] [CrossRef]
- Coraci, D.; Fusco, A.; Frizziero, A.; Giovannini, S.; Biscotti, L.; Padua, L. Global approaches for global challenges: The possible support of rehabilitation in the management of COVID-19. J. Med. Virol. 2020, 92, 1739–1740. [Google Scholar] [CrossRef]
- Mahoney, F.I.; Barthel, D.W. Functional Evaluation: The Barthel Index. Med. Chir. Fac. State Maryl. 1965, 14, 61–65. [Google Scholar]
- Graham, R.C.; Hughes, R.A.C. A modified peripheral neuropathy scale: The Overall Neuropathy Limitations Scale. J. Neurol. Neurosurg. Psychiatry 2006, 77, 973–976. [Google Scholar] [CrossRef]
- Costa, R.; Probst, M.; Bastos, T.; Vilhena, E.; Seabra, A.; Corredeira, R. Behavioural Regulation in Exercise Questionnaire in people with schizophrenia: Construct validity of the Portuguese versions. Disabil. Rehabil. 2018, 40, 2577–2584. [Google Scholar] [CrossRef]
- Rosenberg, M. Society and the Adolescent Self–Image; Princeton University Press: New Jersey, NJ, USA, 1965. [Google Scholar]
- Hubley, A.M. Beck depression inventory. In Encyclopedia of Quality of Life and Well-Being Research; Springer: Amsterdam, The Netherlands, 2014; pp. 338–345. [Google Scholar]
- Apolone, G.; Mosconi, P. The Italian SF-36 Health Survey: Translation, validation and norming. J. Clin. Epidemiol. 1998, 51, 1025–1036. [Google Scholar] [CrossRef]
- Mori, L.; Prada, V.; Signori, A.; Pareyson, D.; Piscosquito, G.; Padua, L.; Pazzaglia, C.; Fabrizi, G.M.; Smania, N.; Picelli, A.; et al. Outcome measures in the clinical evaluation of ambulatory Charcot-Marie-Tooth 1A subjects. Eur. J. Phys. Rehabil. Med. 2019, 55, 47–55. [Google Scholar] [CrossRef]
- Bouhassira, D.; Attal, N.; Fermanian, J.; Alchaar, H.; Gautron, M.; Masquelier, E.; Rostaing, S.; Lanteri-Minet, M.; Collin, E.; Grisart, J.; et al. Development and validation of the neuropathic pain symptom inventory. Pain 2004, 108, 248–257. [Google Scholar]
- Padua, L.; Briani, C.; Jann, S.; Nobile-Orazio, E.; Pazzaglia, C.; Morini, A.; Mondelli, M.; Ciaramitaro, P.; Cavaletti, G.; Cocito, D.; et al. Validation of the Italian version of the Neuropathic Pain Symptom Inventory in peripheral nervous system diseases. Neurol. Sci. 2009, 30, 99–106. [Google Scholar] [CrossRef]
- Portenoy, R. Development and testing of a neuropathic pain screening questionnaire: ID Pain. Curr. Med. Res. Opin. 2006, 22, 1555–1565. [Google Scholar] [CrossRef]
- Giovannini, S.; Coraci, D.; Brau, F.; Galluzzo, V.; Loreti, C.; Caliandro, P.; Padua, L.; Maccauro, G.; Biscotti, L.; Bernabei, R. Neuropathic Pain in the Elderly. Diagnostics 2021, 11, 613. [Google Scholar] [CrossRef]
- Coraci, D.; Giovannini, S.; Loreti, C.; Fusco, A.; Padua, L. Management of neuropathic pain: A graph theory-based presentation of literature review. Breast J. 2020, 26, 581–582. [Google Scholar] [CrossRef]
- Giovannini, S.; Onder, G.; Leeuwenburgh, C.; Carter, C.; Marzetti, E.; Russo, A.; Capoluongo, E.; Pahor, M.; Bernabei, R.; Landi, F. Myeloperoxidase levels and mortality in frail community-living elderly individuals. J. Gerontol.—Ser. A Biol. Sci. Med. Sci. 2010, 65A, 369–376. [Google Scholar] [CrossRef]
- Biscetti, F.; Giovannini, S.; Straface, G.; Bertucci, F.; Angelini, F.; Porreca, C.; Landolfi, R.; Flex, A. RANK/RANKL/OPG pathway: Genetic association with history of ischemic stroke in Italian population. Eur. Rev. Med. Pharmacol. Sci. 2016, 20, 4574–4580. [Google Scholar]
- Vetrano, D.L.; Collamati, A.; Magnavita, N.; Sowa, A.; Topinkova, E.; Finne-Soveri, H.; van der Roest, H.G.; Tobiasz-Adamczyk, B.; Giovannini, S.; Ricciardi, W.; et al. Health determinants and survival in nursing home residents in Europe: Results from the SHELTER study. Maturitas 2018, 107, 19–25. [Google Scholar] [CrossRef]
- Onder, G.; Giovannini, S.; Sganga, F.; Manes-Gravina, E.; Topinkova, E.; Finne-Soveri, H.; Garms-Homolová, V.; Declercq, A.; van der Roest, H.G.; Jónsson, P.V.P.V.; et al. Interactions between drugs and geriatric syndromes in nursing home and home care: Results from Shelter and IBenC projects. Aging Clin. Exp. Res. 2018, 30, 1015–1021. [Google Scholar] [CrossRef]
- Laudisio, A.; Antonelli Incalzi, R.; Gemma, A.; Giovannini, S.; Lo Monaco, M.R.; Vetrano, D.L.; Padua, L.; Bernabei, R.; Zuccalà, G. Use of proton-pump inhibitors is associated with depression: A population-based study. Int. Psychogeriatr. 2018, 30, 153–159. [Google Scholar] [CrossRef]
- Boentert, M.; Dziewas, R.; Heidbreder, A.; Happe, S.; Kleffner, I.; Evers, S.; Young, P. Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: A web-based survey. J. Neurol. 2010, 257, 646–652. [Google Scholar] [CrossRef]
- Padua, L.; Aprile, I.; Cavallaro, T.; Commodari, I.; La Torre, G.; Pareyson, D.; Quattrone, A.; Rizzuto, N.; Vita, G.; Tonali, P.; et al. Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study. Neurol. Sci. 2006, 27, 417–423. [Google Scholar] [CrossRef]
- Redmond, A.C.; Burns, J.; Ouvrier, R.A. Factors that influence health-related quality of life in Australian adults with Charcot-Marie-Tooth disease. Neuromuscul. Disord. 2008, 18, 619–625. [Google Scholar] [CrossRef]
- Lorenzi, M.; Bonassi, S.; Lorenzi, T.; Giovannini, S.; Bernabei, R.; Onder, G. A review of telomere length in sarcopenia and frailty. Biogerontology 2018, 19, 209–221. [Google Scholar] [CrossRef]
- Padua, L.; Shy, M.E.; Aprile, I.; Cavallaro, T.; Pareyson, D.; Rizzuto, N.; Vita, G.; Schenone, A. Correlation between clinical/neurophysiological findings and quality of life in Charcot-Marie-Tooth type 1A. J. Peripher. Nerv. Syst.: JPNS 2008, 70, 64–70. [Google Scholar]
- Carfì, A.; Liperoti, R.; Fusco, D.; Giovannini, S.; Brandi, V.; Vetrano, D.L.; Meloni, E.; Mascia, D.; Villani, E.R.; Gravina, E.M.; et al. Bone mineral density in adults with Down syndrome. Osteoporos. Int. 2017, 28, 2929–2934. [Google Scholar] [CrossRef]
- Hackett, D.; Roberts-Clarke, D.; Jain, N.; Mavros, Y.; Wilson, G.C.; Halaki, M.; Burns, J.; Nicholson, G.; Fiatarone Singh, M.; Fornusek, C. Body composition and its association with physical performance, quality of life, and clinical indictors in Charcot-Marie-Tooth disease: A pilot study. Disabil. Rehabil. 2019, 41, 405–412. [Google Scholar] [CrossRef]
- Roberts-Clarke, D.; Fornusek, C.; Saigal, N.; Halaki, M.; Burns, J.; Nicholson, G.; Fiatarone Singh, M.; Hackett, D. Relationship between physical performance and quality of life in Charcot-Marie-Tooth disease: A pilot study. J. Peripher. Nerv. Syst. 2016, 21, 357–364. [Google Scholar] [CrossRef]
- Pazzaglia, C.; Padua, L.; Pareyson, D.; Schenone, A.; Aiello, A.; Fabrizi, G.M.; Cavallaro, T.; Santoro, L.; Manganelli, F.; Coraci, D.; et al. Are novel outcome measures for Charcot–Marie–Tooth disease sensitive to change? The 6-minute walk test and StepWatchTM Activity Monitor in a 12-month longitudinal study. Neuromuscul. Disord. 2019, 29, 310–316. [Google Scholar] [CrossRef]
- Tozza, S.; Bruzzese, D.; Pisciotta, C.; Iodice, R.; Esposito, M.; Dubbioso, R.; Ruggiero, L.; Topa, A.; Spina, E.; Santoro, L.; et al. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients. Eur. J. Neurol. 2018, 25, 301–306. [Google Scholar] [CrossRef]
- Colomban, C.; Micallef, J.; Lefebvre, M.N.; Dubourg, O.; Gonnaud, P.M.; Stojkovic, T.; Jouve, E.; Blin, O.; Pouget, J.; Attarian, S. Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients. J. Neurol. Sci. 2014, 336, 155–160. [Google Scholar] [CrossRef]
- Pazzaglia, C.; Vollono, C.; Ferraro, D.; Virdis, D.; Lupi, V.; Le Pera, D.; Tonali, P.; Padua, L.; Valeriani, M. Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study. Pain 2010, 149, 379–385. [Google Scholar] [CrossRef]
- Ribiere, C.; Bernardin, M.; Sacconi, S.; Delmont, E.; Fournier-Mehouas, M.; Rauscent, H.; Benchortane, M.; Staccini, P.; Lantéri-Minet, M.; Desnuelle, C. Pain assessment in Charcot-Marie-Tooth (CMT) disease. Ann. Phys. Rehabil. Med. 2012, 55, 160–173. [Google Scholar] [CrossRef]
- Laurà, M.; Hutton, E.J.; Blake, J.; Lunn, M.P.; Fox, Z.; Pareyson, D.; Solari, A.; Radice, D.; Koltzenburg, M.; Reilly, M.M. Pain and small fiber function in charcot-marie-tooth disease type 1A. Muscle Nerve 2014, 50, 366–371. [Google Scholar] [CrossRef]
- Anens, E.; Emtner, M.; Hellström, K. Exploratory study of physical activity in persons with Charcot-Marie-Tooth disease. Arch. Phys. Med. Rehabil. 2015, 96, 260–268. [Google Scholar] [CrossRef]
- Azevedo, H.; Pupe, C.; Pereira, R.; Nascimento, O.J.M. Pain in charcot-marie-tooth disease: An update. Arq. Neuropsiquiatr. 2018, 76, 273–276. [Google Scholar]
- Segura-Jiménez, V.; Estévez-López, F.; Castro-Piñero, J.; Álvarez-Gallardo, I.C.; Soriano-Maldonado, A.; Borges-Cosic, M.; Delgado-Fernández, M. Association of Patterns of Moderate-to-Vigorous Physical Activity Bouts With Pain, Physical Fatigue, and Disease Severity in Women With Fibromyalgia: The al-Ándalus Project. Arch. Phys. Med. Rehabil. 2019, 100, 1234–1242.e1. [Google Scholar] [CrossRef]
- Piscosquito, G.; Reilly, M.M.; Schenone, A.; Fabrizi, G.M.; Cavallaro, T.; Santoro, L.; Vita, G.; Quattrone, A.; Padua, L.; Gemignani, F.; et al. Is overwork weakness relevant in Charcot-Marie-Tooth disease? J. Neurol. Neurosurg. Psychiatry 2014, 85, 1354–1358. [Google Scholar] [CrossRef]
- Tajima, F.; Nakamura, T.; Nishimura, Y.; Arakawa, H.; Kawasaki, T.; Ogawa, T.; Nishiyama, K. Rehabilitation of Charcot-Marie-Tooth disease. Brain Nerve 2016, 68, 59–68. [Google Scholar] [CrossRef]
- Vita, G.; La Foresta, S.; Russo, M.; Vita, G.L.; Messina, S.; Lunetta, C.; Mazzeo, A. Sport activity in Charcot–Marie–Tooth disease: A case study of a Paralympic swimmer. Neuromuscul. Disord. 2016, 26, 614–618. [Google Scholar] [CrossRef]
- Li, C.; Chen, J.H.; Liu, X.H.; Ren, S.Q. Can Physical Exercise Improve the Residents’ Health? Front. Public Health 2021, 9, 707292. [Google Scholar] [CrossRef]
- Burns, J.; Sman, A.; Cornett, K.; Wojciechowski, E.; Walker, T.; Menezes, M.; Mandarakas, M.; Rose, K.; Bray, P.; Sampaio, H.; et al. Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: A randomised, double-blind, sham-controlled trial. Lancet. Child Adolesc. Health 2017, 1, 106–113. [Google Scholar] [CrossRef]
- Prezza, M.; Trombaccia, F.R.; Armento, L. La scala dell’autostima di Rosenberg: Traduzione e validazione italiana. Boll. Di Psicol. Appl. 1997, 223, 35–44. [Google Scholar]
Whole Sample (n = 31) | SG (n = 14) | NSG (n = 17) | p | ||
---|---|---|---|---|---|
Age (years) | (mean ± SD) Range | 45.5 ± 18.9 18–79 | 39.6 ± 21.9 18–79 | 50.4 ± 15.0 18–70 | 0.31 |
M/F | 17/14 | 11/3 | 6/11 | 0.04 | |
BI | (mean ± SD) Range | 82.7 ± 4.0 73–85 | 84.7 ± 0.7 83–85 | 81.0 ± 4.8 73–85 | 0.27 |
ONLS | (mean ± SD) Range | 6.2 ± 1.1 3–8 | 6.3 ± 1.3 3–8 | 6.2 ± 1.2 3–8 | 0.21 |
Whole Sample (n = 31) | SG (n = 14) | NSG (n = 17) | p | ||
---|---|---|---|---|---|
BREQ-2 AM | (mean ± SD) | - | 0.04 ± 0.13 | - | |
BREQ-2 ER | (mean ± SD) | - | 0.23 ± 0.44 | - | |
BREQ-2 INR | (mean ± SD) | - | 1.07 ± 0.75 | - | |
BREQ-2 IDR | (mean ± SD) | - | 2.98 ± 0.09 | - | |
BREQ-2 INTRIN TOT | (mean ± SD) | - | 2.66 ± 0.35 | - | |
BDI-II | (mean ± SD) | 6.03 ± 6.65 | 5.14 ± 6.92 | 6.76 ± 6.53 | 0.11 |
SES | (mean ± SD) | 33.16 ± 4.95 | 33.64 ± 4.66 | 32.76 ± 5.28 | 0.32 |
Whole Sample (n = 31) | SG (n = 14) | NSG (n = 17) | p | |
---|---|---|---|---|
Physical function | 61.3 | 83.9 | 42.6 | 0.001 |
Role physical | 69.4 | 83.9 | 57.4 | 0.33 |
Bodily pain | 72.2 | 83.7 | 62.8 | 0.22 |
General health | 52.8 | 61.3 | 45.8 | 0.03 |
Vitality | 63.1 | 66.8 | 60.0 | 0.17 |
Social function | 77.8 | 86.6 | 70.6 | 0.04 |
Role emotional | 80.6 | 88.1 | 74.5 | 0.09 |
Mental health | 72.0 | 74.9 | 69.6 | 0.006 |
PCS | 42.1 | 49.6 | 35.8 | 0.22 |
MCS | 51.7 | 51.6 | 51.8 | 0.18 |
Whole Sample (n = 31) | SG (n = 14) | NSG (n = 17) | p | ||
---|---|---|---|---|---|
NPSI | (mean ± SD) | 13.2 ± 18.4 | 2.1 ± 4.0 | 22.3 ± 20.6 | 0.001 |
ID pain | (mean ± SD) | 2.0 ±1.2 | 0.1 ± 0.4 | 1.4 ± 1.5 | 0.03 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pazzaglia, C.; Padua, L.; Stancanelli, C.; Fusco, A.; Loreti, C.; Castelli, L.; Imbimbo, I.; Giovannini, S.; Coraci, D.; Vita, G.L.; et al. Role of Sport Activity on Quality of Life in Charcot-Marie-Tooth 1A Patients. J. Clin. Med. 2022, 11, 7032. https://doi.org/10.3390/jcm11237032
Pazzaglia C, Padua L, Stancanelli C, Fusco A, Loreti C, Castelli L, Imbimbo I, Giovannini S, Coraci D, Vita GL, et al. Role of Sport Activity on Quality of Life in Charcot-Marie-Tooth 1A Patients. Journal of Clinical Medicine. 2022; 11(23):7032. https://doi.org/10.3390/jcm11237032
Chicago/Turabian StylePazzaglia, Costanza, Luca Padua, Claudia Stancanelli, Augusto Fusco, Claudia Loreti, Letizia Castelli, Isabella Imbimbo, Silvia Giovannini, Daniele Coraci, Gian Luca Vita, and et al. 2022. "Role of Sport Activity on Quality of Life in Charcot-Marie-Tooth 1A Patients" Journal of Clinical Medicine 11, no. 23: 7032. https://doi.org/10.3390/jcm11237032